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Abstract 
Pathogenic COL2A1 mutations causing haploinsufficiency of type II collagen, result in type 1 
Stickler syndrome which has a high risk of retinal detachment and failure of the vitreous to 
develop normally. Exon 2 of COL2A1 is alternatively spliced, expressed in the eye but not in 
mature cartilage and encodes a region that binds growth factors TGFβ1 and BMP-2. We 
investigated how both a mutation in intron 2 and a normal variant allele altered the efficiency 
of COL2A1 exon 2 splicing and how the latter may act as a predisposing risk factor for the 
occurrence of rhegmatogenous retinal detachment (RRD) in the general population. Using 
both amplification of illegitimate transcripts and allele specific minigenes expressed in 
cultured cells, we demonstrate variability in exon 2 inclusion not only between different 
control individuals, but also between different COL2A1 alleles. We also identify possible 
trans-acting factors that bind to allele specific RNA sequences, and investigate the effect of 
both knockdown and over expression of these factors on exon 2 splicing efficiency. Finally, 
using a specific cohort of patients with RRD and a control population, we demonstrate a 
significant difference in the frequency of the COL2A1 intronic variant rs1635532 between the 
two groups. 
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Introduction 
Rhegmatogenous retinal detachment (RRD; detachment due to holes or tears in the retina) is 
a sight threatening and potentially blinding condition if timely surgical repair is not 
performed. Even with successful repair, visual outcomes may be impaired by delayed 
presentation, macular involvement or sequelae such as proliferative vitreoretinopathy or 
secondary glaucoma.  
In the white European population the reported incidence of retinal detachment is around 1 in 
10,000 per year (Thompson et al 2002, Kirin et al 2013). Although the incidence of myopia 
is higher in Singapore, a study of retinal detachment there (Wong et al 1999) found similar 
frequencies for retinal detachment in the Chinese and Malay populations but the condition 
was less frequent in the Indian population (0.4 in 10,000). RRD is also much rarer in the 
black South African population with a rate as low as 0.46 per 100,000 individual reported 
(Peters 1995). This variation suggests that genetic differences may be a significant 
predisposing risk factor for retinal detachment independent of myopia, however very few 
studies have explored this further. Using a series of 181 cases of retinal detachment Go et al 
(2005) examined the frequency of detachments in siblings and offspring of affected patients 
and found a significantly increased incidence of detachment in siblings of patients compared 
to a control group. Mitry et al (2011) also showed higher sibling recurrence risk, suggesting 
genetic susceptibility for both myopic and non-myopic RRD. More recently a genome wide 
association study of RRD cases and controls in the white European population identified an 
association between a variant (rs267738) in the CERS2 gene and RRD (Kirin et al 2013). 
RRD is also a clinical feature of Stickler syndrome(s) (MIM #18300, 604841, 614134, 
614284) a connective tissue disorder that carries a high risk of retinal detachment (Snead et al 
2011). In addition families with dominantly inherited RRD (MIM #609508) have been found 
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to have mutations in COL2A1, one of the Stickler syndrome loci (Richards et al 2000a, 
2005), suggesting that some cases of apparently sporadic RRD and especially giant retinal 
tear (GRT) may in fact be due to de novo or familial mutations rather than more common 
predisposing genetic factors. To investigate this possibility we analysed a number of patients 
with RRD for COL2A1 mutations, which in turn lead us to examine the role of COL2A1 exon 
2 alternative splicing in RRD. COL2A1 exon 2 encodes a cysteine rich domain that binds 
TGFβ1 and BMP-2, and acts as an antagonist to these growth factors in the eye where it is 
expressed (Ryan et al 1990, Bishop et al 1994, Zhu et al 1999). Regulation of COL2A1 exon 
2 alternative splicing is partially controlled by the nuclear protein TIA-1 and its interaction 
with a conserved AU rich stem loop region in intron 2, just downstream (c.292+4_+41) from 
the end of the exon (McAlinden et al 2005, 2007), however an additional splicing enhancer 
region(s) was predicted to exist further downstream in intron 2, somewhere between the stem 
loop structure and c.292+380 (McAlinden et al 2005). 
Here we examine how a COL2A1 intron 2 mutation and an intron 2 polymorphism affect 
exon 2 inclusion in the mature COL2A1 transcript, and identify potential trans-acting splicing 
factors which interact with these different pre-mRNA sequences. We also examine the 
frequency of a polymorphic variant in a specific cohort of RRD patients compared to normal 
controls. 
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Materials and Methods 
Patients and controls were selected exclusively from the white European population. Studies 
were performed with approval of the local ethics committee (LREC 92/019 and 02/172). 
Informed written consent was obtained in all cases, and adhered to the tenets of the 
declaration of Helsinki. Only patients with horseshoe tears and retinal detachment secondary 
to PVD were recruited to the study group. In addition they had to meet one of three criteria: 
i) Bilateral retinal detachment secondary to posterior vitreous detachment and 
horseshoe retinal tear. 
ii) Unilateral retinal detachment and horseshoe retinal tear(s) in the fellow eye 
iii) Unilateral retinal detachment in an individual, with parents or siblings also with a 
horseshoe tear retinal detachment. 
The control group were drawn from patients who had attended the ophthalmology department 
at Addenbrooke’s hospital for reasons other than retinal detachment and who were over the 
age of 65yr such that the majority would already have experienced a PVD but without 
associated retinal detachment. Posterior vitreous detachment occurs in approximately 70% of 
the British population by the age of 65, but rarely after that age (Foos 1972, Snead et al 1994) 
COL2A1 sequence analysis 
DNA from the first 10 samples collected from the patient group was analysed as previously 
described for pathogenic mutations (Richards et al 2006). All COL2A1 exons, and 
surrounding intronic regions present in the amplified region, were examined for unique 
sequence variants. Unique DNA variants were submitted to the LOVD COL2A1 variant 
database (http://databases.lovd.nl/shared/genes/COL2A1) 
RT-PCR of illegitimate transcripts 
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RNA obtained from cultured dermal fibroblasts was reverse transcribed with superscript II 
(Invitrogen), using a gene specific primer in exon 10 for the reverse transcription. The cDNA 
was amplified through 2 rounds of PCR using Q5 high fidelity polymerase (New England 
Biolabs). The primary amplification used primers in the 5’untranslated region and exon 9. 
The secondary PCR used primers in exon 1 and exon 8 (supplementary Table S1). 
Minigene construction 
Exons 1-7 of COL2A1, minus a 3164bp region of intron 1 (c.85+506-c.86-466) was 
amplified and cloned into the expression vector pcDNA3.1A myc-His (Invitrogen) to create 
minigenes with the c.292+157C>A mutation, and two wild type alleles that differed due to 
polymorphic variants (Table 1). The region c.1–c.85+505 was ligated to the c.86-465-c.531 
region using a BamH I restriction site included in the primers used to amplify each region. 
Cell culture 
Cultured dermal fibroblasts, MIO-M1 Muller cell line (31) and immortalised lens epithelial 
cell lines (Limb et al 2002, Rhodes et al 2006) (9YRCAT, CD5A, CE11560, CE11565, 
CE13300 and DM1931) were maintained in DMEM (4.5 g/L glucose with 2 mM L-
glutamine) with penicillin (100U/ml)/streptomycin (100µg/ml) and supplemented with non-
essential amino acids, ascorbic acid (25µg/ml) and 10 % foetal bovine serum (FBS, Gibco, 
UK). The lens epithelial cells were obtained from either cases of congenital cataract 
(9YRCAT, DM1931) or from the central epithelium of donor lenses (CD5A, CE11560, 
CE11565, CE13300), all were transformed using the SV40 large T antigen (Rhodes et al 
2006, Coleman et al 2014).  
Expression of COL2A1 minigenes and exon 2 splicing assay 
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Immortalised lens epithelial cells obtained from different individuals were transfected and 
allowed to express COL2A1 minigenes for 24 hr before RNA was extracted using RNeasy 
purification kits (Qiagen UK) followed by DNase treatment using an RNase-free kit 
(Ambion). Minigene RNA was reverse transcribed with Superscript II (Life technologies, 
UK) using a vector specific primer (5’agaaggcacagtcgaggctgatcag3’) and amplified using 
either one of two transcript-specific forward primers that bridged the junction of either exon 1 
and exon 3 (5’gggccaggatgtccggcaac3’) or the junction of exon 2 and 3 
(5’cgccactgccagtgggcaac3’) along with a reverse primer located in exon 6 
(5’tttttcacctttgtcacctcgatc3’). Quantitative RT-PCR using a chromo4 real-time fluorescence 
detector (Biorad UK) with SYBR green PCR master mix (Biorad UK) was used to measure 
the relative difference between transcripts containing/lacking exon 2, using a reaction volume 
of 25µl and primers at a concentration of 0.24pmol/µl. After an initial denaturation of 95˚C 
for 3 min, amplification was achieved through 40 cycles consisting of 95˚C 30 sec, 68.5˚C 20 
sec and 72˚C 15 sec. To confirm the specificity of each reaction, the amplified products were 
also analysed by gel electrophoresis to assess the presence of a single PCR product and its 
size. The amount of full length transcript (i.e. including exon 2) was calculated as a 
percentage of the total cDNA amplified from the same RT sample. Each amplification 
reaction was performed in triplicate to determine the relative difference of each transcript. 
This was repeated a further five times to obtain a mean difference and for statistical analysis 
using Student’s T test. 
Affinity purification (RNA direct-capture) of RNA-binding proteins and mass spectrometry 
Synthetic biotinylated RNA oligonucleotides were purchased from Dharmacon (Thermo 
scientific; supplementary Table S2). Nuclear-enriched cell extract was purified from MIO-
M1 cells using a nuclear extract kit (Active Motif). Prior to use biotinylated oligonucleotides 
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were conjugated to pre-equilibrated streptavidin coated M-280 magnetic beads in 1x direct 
capture buffer (20 mM HEPES pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA). The 
oligonucleotide-bead complex was incubated with pre-cleared nuclear extract, 0.5 µg of 
nuclear extract with 10x modified direct capture buffer without KCl (200 mM HEPES pH 
7.9, 2mM EDTA, 60% glycerol) in a total volume of 500µl overnight. After washing, beads 
were boiled directly in modified Laemmli sample buffer containing 0.1M DTT. Proteins were 
separated by SDS-PAGE (10%) and visualised by silver stain using a mass-spectrometry 
compatible silverquest kit (Life Technologies). Liquid chromatography tandem mass 
spectrometry (LCI-MS/MS) and protein identification was performed on isolated and excised 
protein bands by the Cambridge centre for proteomics (http://proteomics.bio.cam.ac.uk/) 
Western blot 
Whole protein extracts from cell lines were prepared in RIPA (10 mM TRIS-HCl, 1mM 
EDTA, 0.5 mM EGTA, 1 % Triton X-100, 0.1 % sodium deoxycholate, 0.1 % SDS, 140 mM 
NaCl) buffer and protein concentration determined using a BCA (bicinchoninic acid) assay 
kit (Pierce). Samples were boiled in modified Laemmli sample buffer containing DTT. 
Proteins were separated by 10% (w/v) SDS polyacrylamide gels and transferred to 
nitrocellulose membranes. Membranes were blocked in 10% skimmed milk in PBST 
(phosphate buffered saline and 0.1% tween 20) for 1 hr at room temperature. Primary 
antibodies applied for western blotting analysis are catalogued in Supplementary Table S3. 
Western blots were visualised using LumiGLO chemiluminescent substrate (Kirkegaard & 
Perry Laboratories) with a GBOX chemiluminescent imager (Syngene) after probing with 
species-specific horseradish peroxidase conjugated secondary antibodies (Santa Cruz). 
siRNA Knockdown 
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CE13300 cells were co-transfected with COL2A1 reporter minigenes and small interfering 
RNA (siRNA; Dharmacon) using RNAi MAX (Invitrogen) followed by Lipofectamine 2000 
(Invitrogen). siRNA oligonucleotides used are listed in Supplementary Table S4. Twenty four 
hours prior to co-transfection, cells were seeded to 1.5 x 10
6
 cell density in 6 well culture 
dishes then transfected with 30 pmol of total siRNA using RNAi MAX. Cells were then co-
transfected with 1 µg of minigene DNA and 50 pmol of siRNA with Lipofectamine 2000. 
RNA was extracted 48 hours post-transfection as described above. The relative abundance of 
the two COL2A1 transcripts was measured using RT-PCR as described above. 
Over expression of RNA binding proteins 
Cells were co-transfected with vectors expressing tagged RNA binding proteins hnRNP L, 
DAZAP1 and TDP-43 with Lipofectamine and Lipofectamine plus reagent (Invitrogen). 
Briefly 2 x 10
6
 cells plated in 6 well culture dishes were transfected with 0.8 µg of reporter 
minigene DNA and (if applicable) co-transfected with an additional 1.6 µg of plasmid 
expressing tagged RNA-binding proteins. RNA was isolated and COL2A1 exon 2 expression 
measured as described above. 
Statistical analysis 
Genetic association for rs1635532 were carried out using Fisher’s exact tests comparing 
allelic distributions in cases and controls, under the assumptions of recessive and co-
dominant models for the G allele. Stata 12.1 software (College Station, TX) was used for all 
the calculations. 
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Results 
COL2A1 sequence analysis 
Sequencing of COL2A1 amplified from 10 patients with RRD, identified intronic variants in 
three of the patients. These were c.292+157C>A in intron 2, c.3112-87delG in intron 44, and 
c.4318-196G>A in intron 53. Initially all three variants were absent from dbSNP 
(http://www.ncbi.nlm.nih.gov/snp/) and also from over 200 DNA samples sequenced as part 
of a COL2A1 diagnostic sequencing service (http://www.cuh.org.uk/addenbrookes-
hospital/services/genetics-laboratories). Subsequently the c.3112-87delG variant in intron 44 
has been submitted to dbSNP (rs573313146), but is not validated and has no frequency data 
associated with it. No other unique DNA variants were detected. Mutation nomenclature is 
based on the human genome reference assembly hg19 and the cDNA sequence 
NM_001844.4 
Splicing analysis 
The effect of these DNA variants on splicing, of the COL2A1 pre-mRNA, was investigated 
using either amplification of illegitimate transcripts from cultured fibroblasts or minigenes. 
No effect on splicing could be found for the c.3112-87delG and c.4318-196G>A variants and 
we classified these as variants with an unknown clinical significance. Illegitimate transcripts 
amplified using RNA from a patient’s skin fibroblast cell line, with the intron 2 
c.292+157C>A mutation, showed both inclusion and exclusion of the alternatively spliced 
exon 2 (Fig 1). Comparison to normal controls and other cases of RRD demonstrated that 
inclusion of exon 2 into the mature transcript was variable between samples. As the patient 
was also heterozygous for an intronic variant rs1635532, we genotyped the RRD and normal 
controls, used for amplification of illegitimate transcripts (Fig 1), to ensure a mixture of 
genotypes for this SNP. Interestingly all those with an rs1635532 G allele produced some 
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exon 2 skipping, whereas the profile of those homozygous for the A allele was variable, 
where two homozygous AA normal controls, produced no detectable exon skipping. It was 
therefore unclear if the mutation was influencing exon 2 splicing efficiency or if as suggested 
by the control samples other factors including the rs1635532 G allele were involved.  
Exon 2 Splicing efficiency 
To be able to determine if there was a quantitative difference in the efficiency of exon 2 
splicing, resulting from the c.292+157C>A mutation and / or other DNA variants within the 
proposed splicing enhancer region, minigenes were created. These would enable differences 
in the efficiency of exon 2 splicing to be assessed for each COL2A1 allele separately using 
the same cell line (i.e. the same genetic background), which would not be possible using 
endogenous illegitimate transcripts. The two COL2A1 alleles of the patient differed in two 
single nucleotide polymorphisms in intron 2 (rs1793953C/T, c.292+176 and rs1635532A/G, 
c.292+258), that were close to the mutation, so we created a second “normal” minigene 
which contained the same polymorphisms as the mutant allele, except for a variable poly(A) 
sequence starting at c.292+264 (The haplotype of each minigene is documented in Table 1). 
These three minigenes were transfected into immortalised lens epithelium cell lines prepared 
from different individuals. RNA isolated from these transfected cells was then used with 
vector / transcript specific primers and real time RT-PCR to determine the ratio of COL2A1 
mRNA including and excluding exon 2, resulting from each minigene. This showed that not 
only was pre-mRNA from the mutant c.292+157C>A minigene less efficient at splicing exon 
2 into the mature transcript but that the patient’s other allele (now referred to as the C-G 
allele, to reflect its haplotype; Table 1) also produced less exon 2 inclusion than the other 
“normal” allele minigene (now referred to as the T-A allele). Minigene assays were repeated 
in 6 different cell lines. In all cases the C-G allele and “mutant” minigenes were less efficient 
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at including exon 2 in the mRNA compared to the T-A allele minigene. However splicing 
efficiencies varied between cell lines (Fig 2). 
These results suggested that not only was exon 2 splicing variable between individuals but 
that other factors, in addition to the intron 2 DNA variants also contribute to exon 2 splicing 
efficiency. In an attempt to identify possible trans-acting splicing factors, which interact with 
the different alleles, we performed direct capture using biotinylated RNA oligonucleotides. In 
addition to the c.292+157C>A mutation, we chose to use the rs1635532 polymorphism for 
capture experiments, as RRD is not a common disorder and the rs1635532 G allele was less 
frequent (18%) in the European population than the rs1793953 C polymorphism (35%). In 
addition the rs1635532 G allele was more common in our cohort of RRD patients (see 
below), also in silico analysis (http://www.umd.be/HSF3/index.html) predicted that the 
rs1635532 alleles potentially had different affinities for trans-acting splicing factors, whereas 
no difference was predicted for the alleles of rs1793953. The other polymorphic SNP 
rs1793957 present in the minigenes was outside of the region predicted to contain additional 
splicing enhancer motifs (McAlinden et al 2005). 
 
RNA Direct Capture 
RNA direct-capture experiments were performed to identify trans-acting factors binding to 
the rs1635532 region within intron 2. Direct capture was performed with biotinylated RNA 
oligonucleotides representing the G and A alleles of rs1635532 with MIO-M1 cell nuclear 
extract. Mass spectrometry identified heterogenous nuclear ribonucleoprotein (hnRNP) 
protein family members hnRNP L and hnRNP A1 as proteins which bound to the G allele 
oligonucleotide and DAZ-associated protein 1 (DAZAP1) as a protein which bound with 
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greater affinity to the A allele oligonucleotide (Fig 3A). These were confirmed by direct 
capture followed by western blotting (Fig 3B). 
Direct capture was repeated with biotinylated RNA oligonucleotides representing the mutant 
and wild type sequence of intron 2 c.292+157C>A. RNA-binding protein TDP-43 was 
identified by mass spectrometry, and Western blot analysis confirmed that TDP-43 had a 
greater affinity for the mutant (A) oligonucleotide compared to the wild-type (C) 
oligonucleotide (Fig 3A and 3B). 
Effect of under and over expression of RNA binding proteins on COL2A1 exon 2 splicing 
RNA binding proteins which showed affinity to RNA oligonucleotides by direct capture and 
western blotting were either under or over expressed, to investigate their effect on COL2A1 
exon 2 splicing efficiency, using minigenes expressed in CE13300 immortalised lens 
epithelial cells. 
hnRNP A1 
hnRNP A1 showed greater affinity for the rs1635532 G allele oligonucleotide (Fig 3A) and 
minigene assays determined that this rarer allele resulted in a decrease in exon 2 inclusion 
(Fig 2). siRNA depletion of hnRNP A1 rescued the exon skipping in the wild-type C-G allele 
minigene with exon 2 inclusion rising from 29% in luciferase siRNA controls to levels 
comparable to the wild-type T-A allele minigene (41%, p = <0.0001, Figure 4). A small 
increase was observed in depleted hnRNP A1 cells transfected with the mutant minigene 
compared to luciferase siRNA controls (Fig 4). hnRNP A1 over expression decreased exon 2 
inclusion in both wild-type C-G allele (18 % exon 2 inclusion) and mutant minigenes (12 % 
exon 2 inclusion) compared to empty vector control where exon 2 inclusion for the C-G allele 
and mutant allele were 28 % (p = 0.0268) and 17 % (p = 0.0106) respectively (Fig 5). 
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TDP-43 
Oligonucleotides representing the c.292+157C>A mutant and wild-type regions of COL2A1 
intron 2 identified that TDP-43 was bound with greater affinity to the mutant RNA sequence 
(Fig 3B). This mutation was determined to reduce exon 2 inclusion by the minigene assay 
(Fig 2). Compared to the luciferase control, siRNA depletion of TDP-43 rescued the exon 2 
skipping observed in cells transfected with mutant minigene to a level of 42 % inclusion (p = 
0.0274). Exon 2 inclusion was also increased significantly in TDP-43 depleted cells 
transfected with wild-type C-G minigene (43 %, p = 0.0001) but had no significant effect on 
splicing using the minigene of the T-A allele. Over-expression of TDP-43 (Fig 5) 
significantly decreased exon 2 inclusion from all three minigenes, with the wild-type T-A 
minigene producing only 17 % exon 2 inclusion compared to 48 % for the empty vector 
control (p = 0.0002), the wild-type C-G minigene (16 % exon 2 inclusion compared to 29 % 
for the empty vector control; p = 0.0172) and the mutant minigene (2 % exon 2 inclusion 
compared to 17 % for the empty vector control; p = <0.0001).  
hnRNP L 
Another hnRNP family member hnRNP L bound with greater affinity to the rs1635532 G 
allele oligonucleotide compared to the A allele oligonucleotide (Fig 3A). siRNA depletion of 
hnRNP L increased exon 2 inclusion in both the wild-type C-G allele and mutant minigenes 
to levels comparable to the wild-type T-A allele (Fig 4). But did not increase the level of 
exon 2 inclusion in RNA from the T-A allele minigene above that seen in the luciferase 
control. Over expression of hnRNP L significantly increased exon 2 inclusion in RNA from 
the wild-type T-A minigene (74 % compared to 48 % for the empty vector control; p = 
0.0005), C-G allele minigene (40 % exon 2 inclusion compared to 29 % for the empty vector 
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control; p = 0.0034) and the mutant minigene (36 % exon 2 inclusion compared to 17 % for 
the empty vector control; p = 0.0006). 
DAZAP1 
Although DAZAP1 binds to both rs1635532 G and A allele oligonucleotides, it bound with 
greater affinity to the A allele oligonucleotide (Fig 3A). DAZAP1 depletion by siRNA (Fig 
4) resulted in almost complete inclusion of exon 2 in the wild type T-A allele minigene (93 
%), wild type C-G allele minigene (88 %) and the mutant minigene (89 %). Surprisingly 
DAZAP1 over-expression (Fig 5) also significantly increased exon 2 inclusion in the wild 
type T-A minigene (65 % exon 2 inclusion compared to 48 % for the empty vector control; p 
= 0.0172), the wild type C-G minigene (40 % exon 2 inclusion compared to 29 % for the 
empty vector control; p = 0.0087) and the mutant minigene (25 % exon 2 inclusion compared 
to 17 % for the empty vector control; p = 0.0156). However over expression did not reach the 
high level of exon 2 inclusion observed when expression of DAZAP1 was reduced. 
Population genotyping and statistical analysis 
As the rs1635532 G allele was shown to result in less efficient COL2A1 exon 2 inclusion in 
the minigene system, we used a Fisher’s exact test to compare distributions of the rs1635532 
alleles between 244 RRD patients and 215 healthy controls, (Table 2) We observed an 
association between the rs1635532 alleles and RRD status. This association was strongest 
and most significant under a recessive model, where individuals homozygous for the G allele 
were more likely to be RRD cases, than subjects with at least one copy of allele A (OR=2.23, 
95% CI 1.16-4.44, p=0.01), but less significant under the assumptions of a co-dominant 
model (OR= 1.31 95%CI 0.98-1.75, p=0.058).  
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Discussion 
Although many “risk alleles” have been identified via genome wide association studies, it is 
probable that to date, only a minority of those have identified the functional DNA sequence 
variant that confers the risk to the disorder under investigation. Here by initially studying the 
effect of a mutation in COL2A1 we also identified a functional effect of a relatively common 
variant rs1635532. We then showed statistically significant association between 
homozygosity for the rs1635532 G allele and a carefully selected cohort of patients with a 
specific type of retinal detachment. As both the mutation and common variant are deep 
within an intron it is unlikely that either of these would have been identified using exome 
sequencing. Indeed the rs1635532 polymorphism does not appear in the exome sequence 
variation database (http://evs.gs.washington.edu/EVS/), this may have implications for other 
studies still searching for a functional difference between alleles of genes identified in 
association studies. 
Functional role of COL2A1 exon 2 
Alternative splicing of COL2A1 is likely to have key regulatory roles in the development of 
both eye and cartilage. The cysteine rich domain encoded by exon 2 is expressed in the eye 
but not in mature cartilage (Sandell et al 1991, Bishop et al 1994), it can bind TGFβ1 and 
BMP-2 (Zhu et al 1999) and therefore act as an antagonist to these growth factors. The role 
of the type II collagen cysteine rich domain in regulating growth factor homeostasis suggests 
that perturbation of this function could play a role in the development of RRD. Type II 
collagen is the major structural component of the vitreous, and under-expression of the 
molecule, due to nonsense mediated decay, is the most common molecular cause of type 1 
Stickler syndrome, where affected patients have a high risk of RRD, as well as high 
congenital myopia due to megalophthalmos, which is unusual as most neonates are born 
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hypermetropic. TGFβ1 homeostasis is known to be disrupted due to mutations in the 
extracellular matrix protein fibrillin (Neptune et al 2003) which result in Marfan syndrome 
(MIM #154700). Like Stickler syndrome, Marfan syndrome has an increased incidence of 
retinal detachment (Nemet et al 2006), suggesting that a possible common molecular 
mechanism (i.e. altered TGFβ1 homeostasis) accounts for the increased risk of RRD seen in 
these two disorders. In mature cartilage COL2A1 exon 2 is not expressed, and in this tissue 
both TGFβ1and BMP-2 have been shown to activate cartilage specific gene expression 
(Murphy et al 2015) explaining why the antagonistic effect of the, exon 2 encoded, cysteine 
rich domain is not required in that particular tissue. This region of the type II collagen N-
propeptide may also be partially retained in heterotypic type II/XI collagen heterotrimers, as 
it has been detected on the outside of collagen fibrils in the vitreous, where it is available for 
interaction with other extracellular matrix molecules or cell receptors (Reardon et al 2000). 
Control of exon 2 alternative splicing 
Regulation of COL2A1 exon 2 splicing is in part controlled by interaction of the RNA 
binding protein TIA-1 with a stem loop structure present between the +4 and +41 region of 
intron 2 pre-mRNA sequence (McAlinden et al 2007). Although it has been shown that 
disruption of this stem loop structure diminished exon 2 inclusion, deletion of bases +11 to 
+380 of intron 2 completely abolished exon 2 inclusion (McAlinden et al 2005). This led the 
authors to suggest the existence of other exon 2 splicing enhancer region(s) further 
downstream from the stem loop region. 
The mutant and polymorphic intron 2 regions, identified here as modifiers of COL2A1 exon 2 
splicing, do not necessarily pinpoint these sequences as part of the proposed additional 
splicing enhancers. Instead the ability of the mutant and polymorphic alleles to bind various 
nuclear proteins may inhibit the efficiency with which other trans-acting splicing factors can 
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bind to intronic splicing enhancer motifs. This effect was best demonstrated by the 
knockdown and over expression of hnRNP A1, where reduction in the expression of this 
protein lead to increased exon 2 inclusion in RNA from the minigene with the rs1635532 G 
allele, to which it bound specifically. Conversely over expression of hnRNP A1 reduced exon 
2 inclusion from the C-G allele minigene, with little or no effect on splicing efficiency from 
the other two minigenes. A similar effect was seen when TDP-43 expression was altered. 
This protein bound preferentially to the mutant allele (but also to the normal alleles) and 
reduction in its expression lead to an increase in exon 2 inclusion in RNA from the mutant 
minigene. As it also had the same effect on RNA from the C-G allele minigene, but not the T-
A allele minigene, this suggests that there is some interaction between the binding of TDP-43 
at the c.292+157C/A nucleotide and hnRNP A1 that inhibits exon 2 inclusion. This also 
corresponds with the observation that hnRNP A1 binds almost exclusively to the rs1635532 
G allele. Over expression of TDP-43 decreased exon 2 inclusion in RNA from all three 
minigenes but had a greater effect on the mutant RNA to which it binds preferentially. 
The result of under and over expression of the RNA binding proteins hnRNP L and DAZAP1 
is more difficult to explain. Particularly for DAZAP1 which increased exon 2 inclusion when 
both under and over expressed, compared to the control samples. Similar results were 
achieved with hnRNP L except under expression had little or no effect using the T-A allele 
minigene, whereas over expression had a much greater effect on RNA from the T-A allele 
minigene than the other two (C-G allele and mutant) minigenes. One explanation for these 
results is that altered splicing efficiency may not be as a direct consequence of binding to 
COL2A1 pre-mRNA sequences, but may instead be secondary to changes in expression of 
other trans-acting splicing factors, caused by altered DAZAP1 and hnRNP L expression. 
Since it is known that expression of splicing factors can themselves be regulated by 
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alternative splicing and other trans-acting splicing factors (Barberan-Soler and Zahler 2008, 
Dreumont et al 2010). 
Results from the minigene experiments can also account for the RT-PCR profiles obtained 
from amplification of illegitimate COL2A1 transcripts using dermal fibroblast RNA. Here 
only very low levels of transcripts were available to be amplified. So in those individuals 
with an rs1635532 G allele, where efficiency of exon 2 inclusion was lower, the likelihood of 
amplifying exon 2 skipped cDNAs is greater than for homozygous rs1635532 A individuals. 
Consequences of misregulation of alternative splicing. 
Alternative splicing is a common feature of many human genes (Pan et al 2008) it allows 
tissue specific expression of different protein isoforms thus increasing the proteomic diversity 
expressed from the human genome. Pathogenic mutations that are present within or that 
affect normal splicing of alternatively spliced exons will therefore usually only affect the 
specific tissues in which they are expressed, or in which they have a particular function that 
cannot be compensated for by other isoforms. For instance, missplicing of exon 8 of the 
VCAN (CSPG2) gene, which results in Wagner syndrome (Miyamoto et al 2005), only affects 
the eye, even though exon 8 is also expressed in other tissues. Mutations in alternatively 
spliced exons can also result in modified phenotypes which are considerably milder than 
related disorders caused by mutations in constitutive exons of the same gene. Examples of 
this type of effect are mutations in USH1C that result in non syndromic hearing loss rather 
than Usher syndrome type 1c (Ouyang et al 2002), mutations in exon 9 of COL11A1 
contribute to a recessive form of type 2 Stickler syndrome instead of fibrochondrogenesis 
(Richards et al 2013), and a mutation in BBS8 that results in retinitis pigmentosa instead of 
Bardet-Biedl syndrome (Riazuddin et al 2010). Polymorphic variants, rather than mutations, 
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have also recently been shown to modify the splicing efficiency of various exons in the 
OPMR1, PCLO and HGMCR genes (Seo et al 2013, Xu et al 2014, Yu et al 2014). 
Mutations in COL2A1 exon 2 that result in nonsense mediated decay and / or some exon 
skipping cause a predominantly ocular form of type 1 Stickler syndrome, with little if any 
systemic features of the disorder (Richards et al 2000b, McAlinden et al 2008). Therefore it 
might be expected that variants / mutations that merely affect the efficiency of exon 2 
inclusion will result in very minor, if any, clinical phenotype. To determine if the functional 
difference detected here for the rs1635532 / c.292+258 G allele had an influence on a 
predisposition to develop retinal detachment, we genotyped a cohort of patients with RRD 
and a control group.  
Analysis of the cohort of RRD patients (Table 2) showed that there were a significantly 
greater number of individuals homozygous for the rs1635532 c.292+258 G allele than there 
were in a control group. Interestingly the patient with the c.292+157C>A DNA change had a 
mutated rs1635532 A allele in addition to a G allele and so did not contribute to the group of 
RRD patients that were homozygous for c.292+258G. As the cohort of RRD patients have 
not had the complete COL2A1 gene sequenced it is unclear what contribution new mutations, 
that subtly alter the expression of the gene, may make towards a predisposition towards RRD. 
We have certainly detected two other sequence changes in the gene (c.3112-87delG and 
c.4318-196G>A) that at present are either very rare or unique to the patients, but have an 
unknown clinical significance. If there is a high incidence of new mutations that contribute to 
RRD, then this will affect the ability to detect association between any particular common 
gene variant and a predisposition to develop RRD, as the mutations could occur de novo on 
any allele. 
Although a previous genome wide association study had not indicated that variants of 
COL2A1 were a predisposing risk factor for RRD (Kirin et al 2013), there may be reasons for 
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this. Firstly in the case of rare disorders such as retinal detachment, association studies are 
severely disadvantaged by the difficulty of recruitment of sufficient subject numbers. 
Attempts to bolster numbers of affected individuals risks degrading any observable 
association by amalgamating different phenotypic sub-groups of retinal detachment, which 
potentially have a different underlying molecular mechanism. For this reason we limited our 
cohort of patients to those resulting from horseshoe retinal tears secondary to pathological 
posterior vitreous detachment and did not include RRD due to round holes, retinal dialysis or 
retinoschisis. Secondly as we have demonstrated here, new mutations in addition to common 
DNA variants may predispose individuals to RRD. 
Despite the relatively low numbers of individuals tested, by focussing on a defined specific 
sub-group of RRD, we found a statistically significant association between the rs1635532 
c.292+258 G allele and RRD associated with posterior vitreous detachment (PVD). Clearly 
this analysis needs to be replicated with other populations in addition to increasing the 
numbers of patients to confirm this association. However the link between the functional 
consequence of the polymorphism, subsequent effect on TGFβ1 and BMP-2 homeostasis, 
and a predisposition towards RRD is persuasive, and is reinforced by the identification of the 
intron 2 mutation which had a similar effect to the polymorphism.  
Other factors must also contribute to the risk of this type of RRD, as many of the normal 
control group were also homozygous for the rs1635532 c.292+258 G allele. It is possible that 
these other factors may modify the effect of the rs1635532 G allele. If they also vary between 
populations, than this may explain why the rs1635532 G allele appears to be more common 
in the African population than Europeans, even though the incidence of RRD in Africans is 
apparently lower (the frequency of the rs1635532 alleles in the African population is only 
based on 46 chromosomes; 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1635532). The current work has 
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also identified potential candidates for these factors, namely molecules involved in 
controlling splicing of exon 2, such as TIA-1 hnRNP A1, and TDP-43, which can potentially 
modify the effect of the rs1635532 G allele. Other candidates include TGFβ1, BMP-2 and 
factors that may, like the COL2A1 exon 2 encoded region, regulate their action. Now that it is 
possible to cost effectively sequence the complete COL2A1 gene (~30kb), by next generation 
sequencing, it should be possible to determine the contribution that both polymorphic 
variation in these candidate genes and mutations in COL2A1 make to the development of 
RRD. If individuals at a high risk of RRD could be identified, in particular those with a 
family history of giant retinal tear, then prophylactic cryotherapy to reduce the risk of 
detachment, as described for treating patients with Stickler syndrome may be a possibility 
(Fincham et al 2014). 
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Figure Legends 
Figure 1. Amplification of illegitimate COL2A1 transcripts from cultured dermal 
fibrobalsts. 
RNA from cultured skin fibroblasts obtained from cases of RRD (RD) including a patient (P) 
with a COL2A1 intron 2 mutation and normal controls (N) was reverse transcribed and 
subjected to two rounds of amplification by PCR, using nested primers for the second 
amplification reaction. Amplified DNA was visualised by agarose gel electrophoresis along 
with size standards (S) where the 500bp standard is indicated. The individuals were also 
genotyped for the SNP rs1635532 to ensure that at both homozygous and heterozygous 
individuals for this variant were included as controls. 
 
Figure 2. Effect of COL2A1 DNA variants on exon 2 splicing in the minigene system. 
Expression of COL2A1 minigenes in lens epithelial cell lines followed by qRT-PCR 
measured exon 2 inclusion. The graph is a quantification of six replicates expressed as means 
± SEM. In 9YRCAT cells exon 2 inclusion with the T-A allele minigene was 41% compared 
to 11% with the C-G allele minigene and 20% with the mutant T-A allele minigene. In CD5A 
cells the corresponding levels of exon 2 inclusion was 34%, 20% and 15% respectively. In 
CE11560 cells 40%, 21% and 22% respectively. In CE11565 cells 31%, 8% and 19 % 
respectively. In CE13300 cells 46%, 25% and 16% respectively. In DM1931 cells 57%, 28% 
and 30% respectively. Levels of exon 2 inclusion which significantly differed between the 
different minigenes for each cell line tested are indicated with an asterisk (* = p<0.05, ** = 
p<0.01, *** = p<0.001). 
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Figure 3. Direct-capture of RNA-binding proteins.  
Silver stained PAGE of proteins captured by RNA oligonucleotides for the G and A alleles of 
rs1635532 (A) or the mutant c.292+157 C>A (B). The position of size standards (kD) loaded 
onto on the gel (but not shown) are indicated. Mass spectrometry identified DAZAP1 as a 
captured protein that appeared to have a greater affinity to the rs1635532 A-allele 
oligonucleotide. Similarly hnRNP A1 and hnRNP L were identified as proteins with affinity 
only to the G allele oligonucleotide. This was confirmed by western blot analysis, where 
hnRNP D, which was not identified by mass spectrometry, served as a negative control for 
the western blot along with a bead only (no oligonucleotide) control for the direct capture. 
TDP-43 was captured by both mutant and wild-type oligonucleotides, however with greater 
affinity to the mutant oligonucleotide, as determined by western blotting. Although SF1 was 
identified by mass spectrometry as a protein that appeared to be captured by the mutant 
oligonucleotide, western blotting did not confirm this difference. Although identified by mass 
spectrometry hnRNP K was not identified by western blot, and so no further analysis was 
undertaken with these two proteins. hnRNP M and hnRNP Q served as negative controls 
along with a bead only control for the direct capture. 
 
Figure 4. The effect of siRNA depletion of RNA-binding proteins on COL2A1 exon 2 
splicing.  
The cell line CE11330 was pre-treated with siRNAs for RNA binding proteins as indicated 
and then transfected with one of three minigenes for different alleles of COL2A1 exons 1-7 
(T/A =T-A allele, C/G= C-G allele, Mt = mutant T-A allele). The amount of exon 2 inclusion 
in mRNA transcribed from each minigene was measured by real time RT-PCR and compared 
to RNA from cells pre-treated with a luciferase siRNA control. Levels of exon 2 inclusion 
which significantly differed from the luciferase control are indicated with an asterisk (* = 
p<0.05, ** = p<0.01, *** = p<0.001; see also results section). Reduction in expression of 
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each RNA binding protein was confirmed by western blotting lysates from the luciferase 
siRNA transfected cells with lysates from cells co-transfected with siRNA targeting a specific 
RNA-binding protein and minigene as indicated. Equal loading was determined by blotting 
for beta-actin.  
 
Figure 5. Effect of RNA-binding protein over-expression on COL2A1 exon 2 splicing.  
Over-expression of hnRNP A1 significantly decreases exon 2 inclusion in mRNA from the 
wild-type C-G allele and mutant minigenes. Both hnRNP L and DAZAP1 over-expression 
significantly increase exon 2 inclusion in mRNA from all three COL2A1 minigenes. Over-
expression of TDP-43 significantly decreases exon 2 inclusion in mRNA from all three 
COL2A1 minigenes. The results are a quantification of six replicates expressed as means ± 
SEM. Levels of exon 2 inclusion which significantly differed from the empty vector control 
are indicated with an asterisk (* = p<0.05, ** = p<0.01, *** = p<0.001). Over-expression of 
each RNA binding protein was confirmed by western blotting using lysates from the non- 
transfected cells compared with lysates from cells co-transfected with an RNA-binding 
protein construct along with a COL2A1 minigene. Equal loading was determined by blotting 
for beta-actin.  
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Table 1 Polymorphic differences between minigenes 
 
Polymorphism Normal “T-A” allele Mutant c.292+157A Normal “C-G” allele 
rs1793953 / c.292+176 T T C 
rs1635532 / c.292+258 A A G 
c.292+264 Poly A region 17As 18As 20As 
rs1793957 / c.293-610 C C G 
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Table 2 Distribution of rs1635532 genotypes in the RRD and control population cohorts. 
NVC = Normal Vitreous Control, RRD = Rhegmatogenous Retinal Detachment 
  NVCs RRDs 
  A G A G 
Totals 298 132 309 175 
Homozygous 98 15 102 35 
Heterozygous 102 102 105 105 
 
 
Page 33 of 38
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig 1  
39x16mm (300 x 300 DPI)  
 
 
Page 34 of 38
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig 2  
200x185mm (72 x 72 DPI)  
 
 
Page 35 of 38
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig 3  
200x197mm (72 x 72 DPI)  
 
 
Page 36 of 38
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig 4  
200x172mm (72 x 72 DPI)  
 
 
Page 37 of 38
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig 5  
200x172mm (72 x 72 DPI)  
 
 
Page 38 of 38
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
